Choosing between non-GLP and GLP toxicology studies is a decision that shapes both the cost and the regulatory readiness of an antibody development program. Non-GLP studies serve early decision-making, while GLP studies form the formal safety package required for an IND filing. Getting the sequence wrong in either direction creates avoidable delays, rework, and capital inefficiency, particularly for programs juggling multiple candidates or novel modalities like bispecifics.
What is the difference between non-GLP and GLP toxicology studies?
Non-GLP studies are exploratory, decision-enabling experiments used before a program commits to a final candidate, while GLP studies are formally regulated safety studies required for IND submission. Non-GLP work typically supports candidate down-selection, modality risk profiling, and dose range finding, generating data quickly without the full documentation burden of Good Laboratory Practice compliance. GLP studies, by contrast, follow strict regulatory standards for study conduct, quality assurance, and data traceability, and they form the core of the IND-enabling safety package reviewed by regulators. Using the wrong study type at the wrong stage is one of the most common causes of timeline slippage in antibody development.
When should a biotech run non-GLP toxicology studies instead of going straight to GLP?
Non-GLP studies should be run whenever a program still has open questions about candidate selection or dose range. This includes early comparisons between lead candidates, initial assessment of modality-specific risks such as cytokine release for bispecifics, and dose range finding studies that inform the design of later GLP work. Running GLP studies before these questions are resolved locks in a candidate prematurely, which is costly if that candidate later proves suboptimal. Non-GLP studies give a development team the flexibility to iterate on candidate choice and dosing strategy before committing to the expense and rigidity of formal GLP testing.
What are the consequences of moving to GLP toxicology studies too early?
Premature GLP testing leads to high cost, limited flexibility, and suboptimal candidate lock-in. Once a GLP study is underway, changing the candidate, dose levels, or study design becomes expensive and disruptive, since GLP studies are designed to be final and regulator-facing rather than iterative. A program that skips proper non-GLP characterization and moves straight to GLP risks discovering, only after the GLP study is complete, that the candidate or dosing regimen was not optimal. This forces teams to repeat the GLP study, doubling both cost and timeline.
What happens if a program delays GLP studies too long?
Delaying GLP toxicology studies past the point where candidate selection is resolved creates its own set of problems: non-acceptable data, study repeats, IND delay, and capital inefficiency. Some programs try to stretch non-GLP data further than it can support, hoping to defer the cost of GLP testing, only to find that regulators require GLP-quality data that the non-GLP studies cannot provide. This forces a late pivot to GLP studies under time pressure, often without the benefit of a well-planned species and dosing strategy. The result is the same core problem as premature GLP testing, cost and delay, but triggered from the opposite direction.
How does Nona Biosciences help programs time the non-GLP to GLP transition correctly?
Nona Biosciences integrates toxicology planning directly into its Idea toward IND (I-to-I®) framework, Nona’s integrated end-to-end service pathway from ideation through IND filing. Rather than treating toxicology studies as a downstream box to check, Nona’s approach builds mechanism-driven models and early species or surrogate planning into the discovery phase itself, so that non-GLP and GLP work are sequenced against real program milestones rather than a generic template. This is particularly important for multispecific antibodies, where multi-target biology risk, asymmetric pharmacokinetics and pharmacodynamics (PK/PD), and species gaps add complexity that conventional monospecific tox planning does not account for. The integrated workflow is designed to make GLP data IND-ready by design, avoiding the rework that occurs when non-GLP data turns out to be insufficient for regulatory purposes.
What additional complexity do bispecific and multispecific antibodies introduce into toxicology planning?
Multispecific antibodies introduce multi-target biology risk, asymmetric PK/PD, species gaps, and assay and CMC challenges that do not apply to conventional monospecific antibodies. Each binding arm can have its own species cross-reactivity profile, which complicates the search for a relevant toxicology species or surrogate molecule.
Nona’s engineering approach starts by addressing the chain mispairing problem inherent to conventional bispecific formats, where heterodimerization of two distinct heavy and light chains generates a mixture of mispaired byproducts alongside the desired bispecific molecule. Fully human heavy-chain-only antibodies (HCAbs), which lack a light chain entirely, remove this mispairing risk at the format level, simplifying both the manufacturing process and the toxicology assessment that follows, since the molecule tested is a single defined species rather than a mixture of chain combinations.
Is non-GLP data ever acceptable for an IND filing?
Non-GLP data alone is not acceptable for an IND filing when it is meant to substitute for the required GLP safety package. Regulators expect the pivotal safety studies supporting first-in-human dosing to meet GLP standards for data integrity and quality assurance. Non-GLP data plays a supporting role, informing candidate selection and dose range so that the GLP study that follows is well-designed and less likely to need repeating. Treating non-GLP data as IND-ready when it was never designed to be is one of the more common and costly mistakes teams make late in a program.
How does timing toxicology studies correctly affect the overall path from antibody identification to IND filing?
Correct timing of non-GLP and GLP studies is one of the biggest levers on the overall timeline from antibody identification to IND filing. Within an integrated, parallel workflow, this path typically runs 12 to 18 months, but most delays come from sequential execution, late alignment between CMC and developability work, poor species planning, and non-GLP data that turns out not to be IND-ready. Programs that plan toxicology strategy alongside discovery and developability work, rather than treating it as a separate downstream step, are far less likely to face rework. Nona’s toxicology and safety assessment capability is built to parallelize these workstreams so that GLP-ready data is available when the program needs it, not months after the fact.
What should a biotech ask a CRO or discovery partner before finalizing a toxicology study plan?
A biotech should ask whether the proposed tox strategy explicitly separates decision-enabling non-GLP work from IND-enabling GLP work, and how species and surrogate planning is being handled for the specific modality involved. It is also worth asking how to select an integrated antibody discovery CRO that can ensure developability data generated earlier in discovery, such as aggregation propensity, thermal stability, and expression yield, feeds into the toxicology study design, since molecules with unresolved developability risk are more likely to behave unpredictably in GLP studies. For bispecific or multispecific programs, ask specifically how the chain mispairing risk of the chosen format was addressed before toxicology studies began, since format-level simplification upstream reduces the risk of ambiguous or hard-to-interpret toxicology results downstream.
Partnering with Nona Biosciences on toxicology strategy means bringing GLP-readiness planning into the discovery phase itself, rather than treating it as a late-stage checkbox. Development teams can connect with Nona’s antibody discovery and toxicology teams early to map a non-GLP to GLP transition plan that fits their specific modality and timeline.
-
Van Norman G.A., Limitations of Animal Studies for Predicting Toxicity in Clinical Trials, JACC: Basic to Translational Science, 2019. Link
-
Bailey G.P. et al., The Use of the Minipig in Biopharmaceutical Safety Assessment, Toxicologic Pathology, 2013. Link
-
Muller P.Y. et al., Guidance for the Design and Analysis of Immunotoxicity Studies in the Development of Biopharmaceuticals, mAbs, 2011. Link
-
Bugelski P.J. et al., Preclinical Development of Therapeutic Monoclonal Antibodies, Journal of Clinical Immunology, 2004. Link
-
Baldrick P., Safety Evaluation of Biological Drugs: What are Toxicology Studies in Primates Telling Us?, Regulatory Toxicology and Pharmacology, 2011. Link
-
Chapman K. et al., Preclinical Development of Monoclonal Antibodies: Considerations for the Use of Non-Human Primates, mAbs, 2009. Link
-
Saber H. et al., An FDA Oncology Analysis of Immune Activating Products and First-in-Human Dose Selection, Regulatory Toxicology and Pharmacology, 2016. Link
